Ayrshire Capital Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,844 shares of the company’s stock after selling 3,016 shares during the quarter. Johnson & Johnson comprises approximately 3.9% of Ayrshire Capital Management LLC’s portfolio, making the stock its 6th largest holding. Ayrshire Capital Management LLC’s holdings in Johnson & Johnson were worth $5,625,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of JNJ. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. FMR LLC increased its holdings in shares of Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. GQG Partners LLC increased its holdings in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.35% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- First Republic Bank Hits New Low, Dimon Pushes for More Cash
- Mullen Automotive: Investment? No. Compelling Speculation, Yes
- GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
- General Mills Retreats To Buy Zone Ahead Of Earnings
- Foot Locker: Slow And Steady Wins The Race
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
